Clinical Trials
69 trialsEVEREST-2
A2 Biotherapeutics Inc.
ACTengine
Immatics US, Inc.
RAINFOL-03
Genmab
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
DUAL-OV-CAR-NK
Beijing Biotech
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
A Study to Evaluate the Efficacy and Safety of CYH33 in Patients With Recurrent/Persistent Ovary Clear Cell Carcinoma
Haihe Biopharma Co., Ltd.
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
ON-5001
OncoNano Medicine, Inc.
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Regeneron Pharmaceuticals
A Phase II Trial of SHR-A1811 in HER2-Expressing Recurrent/Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer
Aadi Bioscience, Inc.
Cemiplimab and ISA101b Vaccine in Adult Participants With Recurrent/Metastatic Human Papillomavirus (HPV)16 Cervical Cancer Who Have Experienced Disease Progression After First Line Chemotherapy
Regeneron Pharmaceuticals
A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer
Jiangsu HengRui Medicine Co., Ltd.
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Arsenal Biosciences, Inc.
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
START
Lyell Immunopharma, Inc.
SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Aprea Therapeutics
p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
Aprea Therapeutics
A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
Akeso
EDO-S101
Mundipharma Research Limited
CHIPRO
Chipscreen Biosciences, Ltd.
Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.
Nykode Therapeutics ASA
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Elucida Oncology
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
ModernaTX, Inc.
Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer
Nykode Therapeutics ASA
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
UP-NEXT
Mersana Therapeutics
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Pfizer
ARIEL2
pharmaand GmbH
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
pharmaand GmbH
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
pharmaand GmbH
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
Xenetic Biosciences, Inc.
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
Kiadis Pharma
Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers
NKGen Biotech, Inc.
Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer
Chipscreen Biosciences, Ltd.
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
Eli Lilly and Company
Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer
Novartis
A Study of TQB2450 Injection in Subjects With PD-L1 Positive Recurrent or Metastatic Cervical Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Phase Ib Study of Chiauranib in Patients With Ovarian Cancer
Chipscreen Biosciences, Ltd.
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
Celgene
An Observational Study of CPT-11 Plus Platinum Analogues Regimens and UGT1A1 Genotypes in Solid Tumors
Daiichi Sankyo
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
Pfizer
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
MEI Pharma, Inc.
Determine if Either of 2 Doses of Study Drug Given With a Low-dose of Cyclophosphamide After a Complete or Partial Response to a Platinum-based Second-line Therapy in Women With Recurrent Ovarian Carcinoma Results in a Longer Time to Progression When Compared to the First Time to Progression.
EMD Serono
OSCA
AstraZeneca